Treatment of Hyperlactatemia in Acute Circulatory Failure Based on

Status Completed

Clinical Trial Summary

The management of a patient with shock is based on improving tissue oxygenation through hemodynamic optimization. Lactate is a marker of tissue hypoperfusion commonly used in the ICU. In principle, hyperlactatemia can be caused by either increased tissue production (tissue hypoperfusion: type A), decreased lactate uptake (type B), or a combination of both mechanisms. It is important to correctly determine the cause(s) of hyperlactatemia, as this determines the treatment (expanders, inotrope, vasopressor, blood derivative transfusion), and the patient's morbidity and mortality. A classic example of this concept is volume expanders, which are frequently used to correct hyperlactatemia secondary to tissue hypoperfusion, but are associated with mortality if used excessively (fluid overload). In clinical practice, it is difficult to differentiate the exact causes of hyperlactatemia (type A and type B). From work carried out over the last 20 years in septic shock and then in other states of shock and in the operating theatre, it has been shown that the arteriovenous CO2 gradient (pCO2gap) measured from arterial and venous blood gases is a marker of tissue hypoperfusion with better predictive ability than the usual markers (clinical examination, SVO2....). Furthermore, when we relate pCO2gap to the arteriovenous O2 difference (pCO2gap /C(a-v)O2), this ratio allows us to distinguish with greater accuracy between states of acute circulatory failure associated with anaerobiosis (tissue hypoperfusion, type A) and those related to the underlying disease. Also, several studies have demonstrated a strong ability of the pCO2gap and the pCO2gap/CavO2 ratio to predict the severity of shock, mortality of the shock patient, hyperlactatemia, and correction of hyperlactatemia with hemodynamic treatment. As a result, many authors have proposed algorithms for the management of shock patients based on the measurement of these CO2-derived indexes. The hypothesis of this study is that the use of an algorithm based on CO2gap and the CO2gap/CavO2 ratio is superior in terms of correction of hyperlactatemia to usual practice based on clinical and macro-hemodynamics.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05032521
Study type	Interventional
Source	Centre Hospitalier Universitaire Dijon
Contact
Status	Completed
Phase	Phase 4
Start date	November 2, 2021
Completion date	November 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05505396` - Hyperglycaemia and Hyperlactataemia in Patients With Severe Acute Brain Injury
Completed	`NCT05145049` - The Relationship of Anesthesia Method With Serum Lactate Level in Craniotomies
Completed	`NCT03025659` - Lactate Acidosis in Postoperative Hearts
Not yet recruiting	`NCT04315623` - RCA for CRRT in Hyperlactatemia Patient With Increased Bleeding Risk	N/A
Completed	`NCT04710875` - The Role of Lactate in Lipolysis and Catabolism in Humans	N/A
Completed	`NCT03078712` - Early Goal Directed Therapy Using a Physiological Holistic View. The ANDROMEDA-SHOCK Study	N/A
Recruiting	`NCT03762005` - Peripheral Perfusion Versus Lactate Targeted Fluid Resuscitation in Septic Shock	N/A
Completed	`NCT04410315` - Hyperlactatemia During and After Tumorcraniotomy
Completed	`NCT02950753` - Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate?	Early Phase 1
Recruiting	`NCT03649009` - Thiamine As An Adjuvant Therapy For Hyperlactatemia In Septic Shock Patients	N/A
Recruiting	`NCT04388267` - Fluid REsponsiveness and Arterial ELASTANCE in Patients With Septic Shock or After Aortic Surgery
Not yet recruiting	`NCT06222021` - Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors	N/A
Not yet recruiting	`NCT04284722` - Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery	Phase 4
Completed	`NCT00270673` - Early Lactate-Directed Therapy in the Intensive Care Unit (ICU)	Phase 3
Not yet recruiting	`NCT05953142` - Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation.	Phase 2
Not yet recruiting	`NCT04046861` - Influence of High Vitamin C Dose on Lactate During and After Extracorporeal Circulation	N/A
Completed	`NCT05649358` - Pilot Testing a Novel Non-invasive Lactate Sensor	N/A
Completed	`NCT00390273` - Effect of Metformin on Lactate Metabolism	Phase 1/Phase 2
Completed	`NCT00471614` - Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine	Phase 2
Completed	`NCT04299815` - Lactate in the Gut	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Treatment of Hyperlactatemia in Acute Circulatory Failure Based on Analysis of CO2: a Prospective Randomized Superiority Study (The LACTEL Study) — LACTEL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms